3 ASX 200 shares tipped to climb 130% (or more) in the next 12 months

Analysts are bullish about the outlook for these shares.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares on the S&P/ASX 200 Index (ASX: XJO) tumbled on Tuesday, closing the day 1.39% lower thanks to broad based losses across multiple sectors. While the day's trading may have disappointed some investors, there are some companies on the index which are expected to shoot higher this year.

Here are three that I have my eye on. And they're all tipped to rise at least 130% over the next 12 months.

A business person directs a pointed finger upwards on a rising arrow on a bar graph.

Image source: Getty Images

Catapult Sports Ltd (ASX: CAT

Catapult is a global sports data and analytics company that provides real-time data to optimise athletes' performance. The tech company reported a 16% revenue uplift in the first half of FY26 and a 19% hike in its annualised contract value (ACV). Catapult expects to maintain strong ACV growth through the second half of FY26, driven by low customer churn and ongoing improvements in margins and cash flow. 

Catapult is quickly gaining traction, and its recurring subscriptions means it benefits from customer retention. That translates to a higher and more stable margin. 

The ASX 200 company's shares were caught up in broad market sell-off on Tuesday, closing 7% lower for the day at $3.29 a piece. The drop means the shares are now 8% lower for the year. But analysts predict the shares could climb as high as 138% to $7.83 over the next 12 months.

Mesoblast Ltd (ASX: MSB)

Mesoblast is an Australian clinical-stage biotech stock that develops and commercialises allogeneic cellular medicines to treat complex diseases. Some products are already in use, and other cell therapies are in the late stages of clinical trials. 

The business has great potential for robust growth this year. Its products are gaining traction and the business is well-funded. The stock has tumbled over the past week but I think this looks like a buying opportunity rather than a reason to panic. If momentum starts to pick up pace the share price can recover its losses quickly. 

At the close of the ASX on Tuesday, the ASX 200 biotech shares were down 3% at $2.01. But analysts are bullish that there is good upside ahead. There is a strong buy consensus and a maximum target price of $4.92. That implies a potential 145% upside at the time of writing. 

Block Inc (ASX: XYZ)

Block, formerly Square, is a global company best known for providing payment-acquiring and related services to businesses. The company posted some strong profit results late last year but has been caught in a perfect storm of headwinds. These include rising interest rates, regulatory scrutiny, and concerns about buy now, pay later models. The combination slashed investor sentiment towards the end of 2025. 

The sell-off has continued into 2026. However, an uptick in investor interest late last week, following the company's results, resulted in a 26% increase in the share price in the past 5 days alone. Analysts think the share price could jump another 186% to $256 over the next 12 months.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Block and Catapult Sports. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Growth Shares

2 of the best Aussie ASX 200 shares to buy and hold for 10 years

Two quality stocks with global growth runways and 40% to 100% potential upside.

Read more »

Green stock market graph.
Growth Shares

2 ASX 200 shares I rate as top buys for growth

I’m excited about the long term of these stocks.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Growth Shares

2 ASX 200 shares that turned a $5,000 investment into $10 million

These shares have generated enormous returns.

Read more »

A woman with a magnifying glass adjusts her glasses as she holds the glass to her computer screen and peers closely at it.
Growth Shares

3 ASX growth shares you'll wish you'd bought at these cheap prices

These high-quality growth businesses are now trading well below prior peaks.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Growth Shares

Experts rate these 2 ASX growth shares as buys this month!

These businesses are predicted to make double-digit returns.

Read more »

A man in a suit looks surprised as he looks through binoculars.
Gold

This ASX stock soared 435% in 12 months, and is tipped to keep climbing

This ASX stock has hugely outperformed the ASX 300 over the past 12 months.

Read more »

Three excited business people cheer around a laptop in the office
Growth Shares

3 ASX 200 shares to buy and hold for a decade or more

If you’re building a 10-year portfolio, these ASX 200 stocks offer powerful structural tailwinds.

Read more »

Person using a calculator with four piles of coins, each getting higher, with trees on them.
Growth Shares

2 strong Australian stocks to buy now with $6,000

These businesses look too good to ignore…

Read more »